In addition, our optimized protocol may be used to monitor the effect of therapeutic strategies, such as mucolytic therapies targeting disulfide crosslinks with reducing agents, or novel CFTR-directed therapeutics targeting the underlying basic defect in patients with CF (Shak et al., 1990; Rubin, 2006; Henke and Ratjen, 2007; Lai et al., 2009; Mall et al., 2018; Ehre et al., 2019; Fernandez-Petty et al., 2019; Middleton et al., 2019; Patarin et al., 2020; Morgan et al., 2021). The gene discussed is CFTR; the disease is cystic fibrosis.